Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways
Open Access
- 21 November 2014
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 125 (1), 141-156
- https://doi.org/10.1172/jci75852
Abstract
MicroRNA-21 (miR-21) contributes to the pathogenesis of fibrogenic diseases in multiple organs, including the kidneys, potentially by silencing metabolic pathways that are critical for cellular ATP generation, ROS production, and inflammatory signaling. Here, we developed highly specific oligonucleotides that distribute to the kidney and inhibit miR-21 function when administered subcutaneously and evaluated the therapeutic potential of these anti–miR-21 oligonucleotides in chronic kidney disease. In a murine model of Alport nephropathy, miR-21 silencing did not produce any adverse effects and resulted in substantially milder kidney disease, with minimal albuminuria and dysfunction, compared with vehicle-treated mice. miR-21 silencing dramatically improved survival of Alport mice and reduced histological end points, including glomerulosclerosis, interstitial fibrosis, tubular injury, and inflammation. Anti–miR-21 enhanced PPARα/retinoid X receptor (PPARα/RXR) activity and downstream signaling pathways in glomerular, tubular, and interstitial cells. Moreover, miR-21 silencing enhanced mitochondrial function, which reduced mitochondrial ROS production and thus preserved tubular functions. Inhibition of miR-21 was protective against TGF-β–induced fibrogenesis and inflammation in glomerular and interstitial cells, likely as the result of enhanced PPARα/RXR activity and improved mitochondrial function. Together, these results demonstrate that inhibition of miR-21 represents a potential therapeutic strategy for chronic kidney diseases including Alport nephropathy.Keywords
This publication has 53 references indexed in Scilit:
- AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial functionJCI Insight, 2013
- MicroRNA Circuits in Transforming Growth Factor-β Actions and Diabetic NephropathySeminars in Nephrology, 2012
- MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic PathwaysScience Translational Medicine, 2012
- mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in miceJCI Insight, 2011
- miR-21 and miR-214 Are Consistently Modulated during Renal Injury in Rodent ModelsThe American Journal of Pathology, 2011
- Identification of a microRNA signature of renal ischemia reperfusion injuryProceedings of the National Academy of Sciences, 2010
- Multiple loci associated with indices of renal function and chronic kidney diseaseNature Genetics, 2009
- Prevalence of CKD in the United States: A Sensitivity Analysis Using the National Health and Nutrition Examination Survey (NHANES) 1999-2004American Journal of Kidney Diseases, 2009
- Potent inhibition of microRNA in vivo without degradationNucleic Acids Research, 2008
- Mpv17l protects against mitochondrial oxidative stress and apoptosis by activation of Omi/HtrA2 proteaseProceedings of the National Academy of Sciences of the United States of America, 2008